After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.
RPCAR01 starts a phase 1 study, albeit one sponsored by academics.
Emilta-L continues to show worse efficacy than a rival ADC discontinued by Pfizer.
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
Early data with ELVN-001 hold up well against olverembatinib and TERN-701.
IBI3020 beats Chengdu Kanghong's KH815 into clinical trials.
